Does Illumina stock pay a dividend?
Apr 17, 2022 · Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 1.2% and is now trading at $249.05.
What is the price of Illumina today?
A Delaware jury on Friday ordered Illumina Inc to pay more than $333 million to a U.S. unit of Chinese genomics company BGI Group after finding …
What are analysts'target prices for Illumina's stock?
Illumina (ILMN) Nasdaq Global Select ILMN $249.05 -$42.67 -14.6% Price as of May 6, 2022, 4:00 p.m. ET View Interactive ILMN Charts The company develops, manufactures, and markets …
Is Illumina stock a buy at $383?
May 17, 2020 · Illumina Inc NASDAQ : ILMN - USD $234.03 + $16.61 ( + 7.64%) DIAGNOSTICS & RESEARCH 3 hours ago Buy Illumina Stocks Fact checked Illumina Inc (ILMN) is a leading diagnostics & research business based in the US. It opened the day at $223.10 after a previous close of $217.42.
Is Illumina a buy right now?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 7 hold rati...
How has Illumina's stock been impacted by COVID-19 (Coronavirus)?
Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organ...
When is Illumina's next earnings date?
Illumina is scheduled to release its next quarterly earnings announcement on Tuesday, April 26th 2022. View our earnings forecast for Illumina .
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Thursday, February, 10th. The life sciences company reported $0.75 earnings per share f...
What guidance has Illumina issued on next quarter's earnings?
Illumina updated its FY 2022 earnings guidance on Monday, February, 28th. The company provided earnings per share guidance of $4.000-$4.200 for the...
What price target have analysts set for ILMN?
10 brokerages have issued twelve-month target prices for Illumina's stock. Their forecasts range from $340.00 to $480.00. On average, they expect I...
Who are Illumina's key executives?
Illumina's management team includes the following people: Francis A. deSouza , President, Chief Executive Officer & Director Robert P. Ragusa ,...
What is Francis deSouza's approval rating as Illumina's CEO?
496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com . Francis deSouza has an approval rating of 92% among Illumina's employees....
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Thermo Fisher Scientific (TMO) , Agilent Technologies (A) , Mettler-Toledo International (MT...
Recently Viewed Tickers
Illumina Inc
Visit a quote page and your recently viewed tickers will be displayed here.
Is Illumina taking over the Grail?
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.
Who bought Grail?
Last week, the EU announced that it was preparing to launch a full-scale probe into a pending merger. On Thursday, Illumina said it is committed to re-acquire Grail.
What are the characteristics of growth stocks?
Illumina announced the $8 billion cash-and-stock deal for startup Grail last September, buying out investors including Amazon founder Jeff Bezos, to regain control of a company it spun out five years ago. Reuters • 4 days ago.
Why did Donald Blakstad use his account?
The best growth stocks have 3 traits: strong fundamentals, great technicals, and a history of Big Money activity in the shares. Outlier stocks see a lot of Big Money buying. Motley Fool • 5 days ago.
What is DNA data storage alliance?
(Bloomberg) -- A San Diego investor on trial for financial fraud told a jury he used a company account that mixed investors’ money with his own to pay for trips to a strip club and casinos, but denied doing anything illegal.Donald Blakstad took the witness stand in a Manhattan court and said he used an account for his company -- Midcontinental Petroleum -- for personal and business expenses because there is a lien on his accounts for unpaid taxes. The personal expenses also included the purchase
What is the Grail biotech?
The DNA Data Storage Alliance, an organization of more than 25 leading companies formed by Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASDAQ: ILMN) and Western Digital (NASDAQ: WDC) together with Microsoft Research, today announced its first white paper titled "Preserving our Digital Legacy: An Introduction to DNA Data Storage."
How to calculate Illumina's P/E ratio?
Five years ago, Illumina (NASDAQ: ILMN) created Grail, a liquid biopsy biotech that hopes to detect as many as 50 types of cancers with a single blood draw from patients . Grail was all set for its initial public offering when Illumina made an $8 billion offer to reacquire the company.
What is the environmental score of Illumina?
Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0271. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
What is the ESG score of Illumina?
Illumina's environmental score of 2.22 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Who is Jing Jun Ma?
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Illumina's overall score of 9.18 (as at 12/31/2018) is excellent – landing it in it in the 2nd percentile of companies rated in the same sector.
Overview of Illumina
Jing Jun Ma is a tech and data expert with more than a decade of experience in digital marketing and programming. He wrangles data to make it useful for consumers facing a decision.
Illumina Trading Volume and PE
Illumina is an American Health Care Medical Equipment & Devices company currently traded on the NASDAQ which fully known as the National Association of Securities Dealers Automated Quotations exchange.
How To Buy Illumina Stock Guide
Illumina currently has 146M active shares in circulation traded through the NASDAQ exchange.
How To Buy Illumina Stock Explained
When investing in Illumina you have several options as to what type of investment you wish to conduct. You can buy traditional Illumina shares with one of our listed brokers or you can trade what is known as CFDs or contracts for difference.
How To Buy Illumina Stock Frequently Asked Questions
Trading the financial markets with Illumina stock can be demanding, even for experienced traders.
Alternative Brokers That You Can Buy Illumina With
Illumina is an American Health Care Medical Equipment & Devices company currently traded on the NASDAQ.
Illumina Broker VS Broker Comparisons
If you feel some of the above Illumina brokers are not quiet what you are looking for or perhaps you would just like to see some alternatives. See our highly rated list of Illumina broker alternatives below.
How much revenue did Illumina have in 2019?
You can read some of our Illumina broker comparisons. We compare side by side some of our best rated Illumina brokers. Read some broker VS broker pages below to compare brokers side by side.
How much is Illumina's revenue in 2020?
Solid annual and quarterly financial performance. In fiscal 2019, Illumina's revenue rose by 6% on a year-over-year basis to roughly $3.5 billion. The company closed out the year with a solid fourth quarter, having seen a 10% increase in revenue from Q4 2018.
What company did Illumina acquire?
Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. The company reported a 72.1% gross margin and $241 million in free cash flow. As for any forward-looking projections for 2020, Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic.
